Influence of genetic polymorphisms on the plasma concentrations of oral tyramine applique - pharmacogenetics biogenic amines

Status

Recruiting

Phases

Unknown

Study type

Interventional

Source

DRKS

Registry ID

DRKS00008915

Enrollment

100

Registered

2015-07-17

Start date

2014-05-22

Completion date

Unknown

Last updated

2025-04-07

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Healthy participants

Interventions

Group 1: 400 mg Tyramin orally once

Eligibility

Sex/Gender

All

Age

18 Years to 50 Years

Inclusion criteria

Inclusion criteria: Subjects between 18 and 50 years of age. Body weight between 50 and 100 kg, while body mass index 18 to 30.

Exclusion criteria

Exclusion criteria: Any known chronic disease significantly increasing cardiovascular risk profile. This is but not limited to: Diabetes mellitus, arterial hypertension, heart failure, status post myocardial infarction, Post-bypass OP or percutaneous transluminal angioplasty, Post-stroke, renovascular disease. Known intolerance to tyramine. Need for any regular medication other than oral contraceptives.

Design outcomes

Primary

Measure	Time frame
Area under the plasma concentration-time curve of tyramine for the first 6 hours after oral administration of 400 mg of tyramine depending on congenital genetic variants with significance for transport proteins, metabolizing enzymes and components relevant to the effects of biogenic amines pathways.	—

Secondary

Measure	Time frame
Plasma concentrations of tyramine before taking 400 mg tyramine, plasma concentrations and area under the plasma concentration-time curves of other endogenous and exogenous biogenic amines insofar as they are detectable (e.g. Adrenalin, Tryptamin, Noradrenalin, Putrescin, Isoamylamin, Dopamin, Cadaverin, Agmatin, Serotonin, Phenylethylamin, Isopropanolamin, Histamin, Spermidin, Cholin, Gamma-Aminobuttersäure, Octopamin, 5-Methoxyindol Ethylamin, Synephrin, 5-Methoxytryptamin, Colamin, Cysteamin, Beta-Alanin), in the urine excreted amounts of primary and secondary amines measured with and without enzymatic cleavage - each depending on congenital genetic variants with significance for transport proteins, metabolizing enzymes and components relevant to the effects of biogenic amines pathways.	—

Measure

Time frame

Plasma concentrations of tyramine before taking 400 mg tyramine, plasma concentrations and area under the plasma concentration-time curves of other endogenous and exogenous biogenic amines insofar as they are detectable (e.g. Adrenalin, Tryptamin, Noradrenalin, Putrescin, Isoamylamin, Dopamin, Cadaverin, Agmatin, Serotonin, Phenylethylamin, Isopropanolamin, Histamin, Spermidin, Cholin, Gamma-Aminobuttersäure, Octopamin, 5-Methoxyindol Ethylamin, Synephrin, 5-Methoxytryptamin, Colamin, Cysteamin, Beta-Alanin), in the urine excreted amounts of primary and secondary amines measured with and without enzymatic cleavage - each depending on congenital genetic variants with significance for transport proteins, metabolizing enzymes and components relevant to the effects of biogenic amines pathways.

—

Countries

Germany

Contacts

Public ContactJürgen Brockmöller

Institut für Klinische PharmakologieUniversitätsmedizin Göttingen

jbrockm@gwdg.de+49 551 39 5770

Outcome results

None listed

Source: DRKS (via WHO ICTRP) · Data processed: Feb 4, 2026